Payment overview · 2025
General Payments
$619.62
18 reported records · 9 companies
Healthcare provider profile · identity verified
Alexis Houser
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MELBOURNE, FL · NPI 1407488778
Verified facts
What the public records show
CMS Open Payments records show Alexis Houser received $619.62 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $170.10 | 27.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 20.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.34 | 15.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $72.95 | 11.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.51 | 9.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.23 | 7.8% | 3 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $19.24 | 3.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.23 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.02 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $619.62 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $170.10 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $94.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.46 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 152 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
152 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 466 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 461 | 143 |
| Lisinopril | Lisinopril | 377 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 117 |
| Alprazolam | Alprazolam | 351 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 115 |
| Losartan Potassium | Losartan Potassium | 312 | 99 |
| Metformin Hcl | Metformin Hcl | 234 | 80 |
| Omeprazole | Omeprazole | 178 | 56 |
| Gabapentin | Gabapentin | 166 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 52 |
| Temazepam | Temazepam | 163 | 30 |
| Mounjaro | Tirzepatide | 152 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 44 |
| Simvastatin | Simvastatin | 146 | 48 |
| Trazodone Hcl | Trazodone Hcl | 144 | 53 |
| Montelukast Sodium | Montelukast Sodium | 137 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 43 |
| Tramadol Hcl | Tramadol Hcl | 113 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 37 |
| Azithromycin | Azithromycin | 104 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 25 |
| Prednisone | Prednisone | 85 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 27 |
| Ezetimibe | Ezetimibe | 78 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 28 |
| Allopurinol | Allopurinol | 75 | 24 |
| Bupropion Xl | Bupropion Hcl | 70 | 26 |
| Furosemide | Furosemide | 69 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 53 |
| Sertraline Hcl | Sertraline Hcl | 66 | 25 |
| Repatha Sureclick | Evolocumab | 65 | 16 |
| Famotidine | Famotidine | 64 | 31 |
| Lorazepam | Lorazepam | 64 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 15 |
| Atenolol | Atenolol | 52 | 16 |
| Meloxicam | Meloxicam | 51 | 17 |
| Ozempic | Semaglutide | 50 | 15 |
| Potassium Chloride | Potassium Chloride | 49 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 42 |
| Buspirone Hcl | Buspirone Hcl | 45 | 17 |
| Estradiol | Estradiol | 39 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Glipizide | Glipizide | 38 | 16 |
| Ibuprofen | Ibuprofen | 37 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 13 |
| Valsartan | Valsartan | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 29 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | 14 |
| Finasteride | Finasteride | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 14 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $619.62 · 18 records | Lilly USA, LLC | BREZTRI, Cologuard Collection Kit, MOUNJARO, Ozempic, SYNTHROID, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, Wegovy, Xhance, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error